Brand Intelligence Graphcompany
Company Overview
About Quest Diagnostics
Quest Diagnostics is the nation's leading provider of diagnostic information services, founded in 1967 as MetPath and headquartered in Secaucus, New Jersey, trading on NYSE (DGX). The company processes approximately 230 million clinical laboratory tests annually, serving patients through approximately 2,250 patient service centers, physician offices, hospitals, and health plans across the United States. For FY2024, Quest generated approximately $9.8 billion in total revenues under CEO James Davis, who succeeded Steve Rusckowski in 2022 and has accelerated the company's strategy of expanding consumer access, digital connectivity with ordering physicians, and advanced specialty testing capabilities in oncology, genetics, and infectious disease.
Business Model & Competitive Advantage
Quest's network of regional laboratories and patient service centers creates geographic density that enables same-day or next-day specimen processing for most clinical testing, with routine tests including blood counts, metabolic panels, lipid profiles, and urinalysis generating high-volume, lower-margin base revenue. Advanced diagnostics—including genomic sequencing for hereditary cancer risk, liquid biopsy (Signatera), advanced cardiovascular testing (QHeartHealth), and toxicology—represent the higher-margin growth opportunities where Quest is investing in laboratory technology and clinical bioinformatics. The company's 2022 acquisition of Haystack Oncology and multiple hospital outreach laboratory acquisitions in 2023-2024 expand its oncology testing footprint.
Competitive Landscape 2025–2026
In 2025-2026, Quest competes primarily with Labcorp (LH) in national commercial laboratory testing and with hospital laboratory systems for in-patient and affiliated outpatient testing. Value-based care models create headwinds for traditional fee-for-service laboratory testing volumes, while the shift toward at-home testing (as demonstrated by COVID-19 at-home tests) creates both threats and opportunities for Quest's consumer-direct strategy. Quest's app-based test ordering, result delivery, and direct-to-consumer health monitoring capabilities are designed to build consumer loyalty beyond physician referrals. The federal No Surprises Act and commercial payer reimbursement pressure on laboratory test rates create ongoing margin management challenges across routine testing categories.
The Quest Diagnostics Story
Founders
Recent Activity
View all →Company Timeline
Major milestones in Quest Diagnostics's journey
Leadership Team
Meet the leaders behind Quest Diagnostics
James E. (Jim) Davis
Jim Davis became CEO and President of Quest Diagnostics on November 1, 2022, succeeding Steve Rusckowski, and was elected Chairman of the Board effective April 1, 2023. Prior to Quest, Davis served as CEO of InSightec, Inc., a medical device company, and held senior management positions during a two-decade career in General Electric's aviation and healthcare businesses, including leading GE's MRI business for five years. He holds master's degrees in management and science from MIT's Sloan School of Management and a bachelor's degree in aeronautical engineering from the University of Michigan.
Sam Samad
Sam Samad serves as Executive Vice President and Chief Financial Officer, overseeing Quest Diagnostics' financial strategy, investor relations, and fiscal operations supporting the company's growth initiatives and strategic acquisitions.
Michael E. Prevoznik
Michael E. Prevoznik serves as Senior Vice President and General Counsel, managing legal affairs, regulatory compliance, and corporate governance for Quest Diagnostics' nationwide operations.
Paul A. Brown, MD
Dr. Paul A. Brown founded Metropolitan Pathology Laboratory (later MetPath, predecessor to Quest Diagnostics) in 1967 with a $500 loan from his father-in-law. As a pathology resident amazed by sky-high hospital test prices, Dr. Brown pioneered the independent clinical laboratory model focused on improving accuracy and reducing costs for outpatient laboratory testing.
Kenneth Freeman
Kenneth Freeman served as the first CEO of the newly independent Quest Diagnostics following its 1996-1997 spinoff from Corning. Freeman inherited a company bleeding cash with nearly $1.2 billion in debt and a $626 million loss, successfully orchestrating a turnaround that established Quest as a leading independent clinical laboratory.
Steve Rusckowski
Steve Rusckowski served as CEO from 2012 to 2022, leading Quest Diagnostics through significant expansion including the launch of QuestDirect consumer-initiated testing (2018), COVID-19 testing services (2020), and numerous strategic acquisitions. His leadership modernized Quest's technology infrastructure and expanded the company's advanced diagnostics portfolio.
Key Differentiators
Market Leader
Quest Diagnostics is recognized as a market leader in the Healthcare Tech sector, demonstrating strong industry presence and customer trust.
Enterprise Scale
With $9.8B in revenue, Quest Diagnostics operates at enterprise scale with proven market validation.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Danaher Corporation
Danaher Corporation is a Washington, D.C.-based global science and technology company — publicly traded on the New York Stock Exchange (NYSE: DHR) as an S&P 500 Health Care component — developing, man
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Quest Diagnostics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Quest Diagnostics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Quest Diagnostics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Quest Diagnostics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →